Male: There is no clear effect on seminal proteins and we anticipate indirect alterations in spermatogenesis
The FDA's 2023 and 2024 actions against compounding pharmacies cited concerns about purity, potency, and sterility of BPC-157 products 3
Is BPC-157 FDA Approved in 2026
A second family, BPC-157 and TB-500, targets tissue repair rather than the GH axis: BPC-157 is proposed to work through angiogenesis, nitric-oxide signaling, and anti-inflammatory activity, while TB-500 binds actin to promote cell migration, blood-vessel formation, and collagen deposition
Weber believes the massive success of the GLP-1 drugs for diabetes and weight loss has lent an air of credibility to these injectable wellness peptides, even though those drugs underwent extensive human trials before coming to market